PET in abdominal pathology: advantages and limitations

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Current oncologic procedures increasingly focus on tumor biology for personalized treatments.
• Clinicians require advanced functional and metabolic information beyond traditional radiologic imaging for patient management.
• There is a need for dynamic follow-up methods in cancer care.

Purpose of the Study:

• To highlight the role of Nuclear Medicine and positron emission tomography (PET) in providing functional and metabolic data for oncologic purposes.
• To discuss the utility of 2-((18)F)fluoro-2-desoxi-D:-glucose PET in abdominal diseases.
• To emphasize the importance of integrating PET findings with radiologic imaging for treatment decisions.

Main Methods:

• Review of the application of Nuclear Medicine and PET in oncology.
• Focus on 2-((18)F)fluoro-2-desoxi-D:-glucose PET for assessing tumor metabolic characteristics.
• Integration of PET data with conventional radiologic imaging results.

Main Results:

• 2-((18)F)fluoro-2-desoxi-D:-glucose PET provides crucial metabolic information for oncologic diagnosis and treatment planning.
• PET imaging can significantly influence treatment choices, particularly in abdominal diseases.
• PET findings, when combined with radiologic imaging, enhance diagnostic accuracy.

Conclusions:

• Nuclear Medicine, especially 2-((18)F)fluoro-2-desoxi-D:-glucose PET, is a valuable tool for personalized cancer treatment by revealing tumor metabolic features.
• While widely used and informative, the specificity of PET in certain conditions, like abdominal diseases, must be carefully evaluated.
• The integration of PET with radiologic imaging is essential for comprehensive patient management and treatment response assessment.